摘要:
Cloning and expression of DNA segments encoding bovine GM-CSF, and processes for producing recombinant bovine GM-CSF as a product of recombinant cell culture, are disclosed.
摘要:
A process for preparing bovine interleukin I.beta. (bIL-1.beta.) by culturing a microbial host transformed by a vector containing a DNA sequence encoding bIL-1.beta. under conditions suitable for the expression of bIL-1.beta. and recovering bIL-1.beta..
摘要:
Cloning and expression of nucleotide DNA segments encoding bovine IL-1.beta., and processes for producing purified bovine IL-1.beta. as a product of recombinant cell culture, are disclosed.
摘要:
Cloning and expression of DNA segments encoding bovine IL-1.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.
摘要:
Cloning and expression of DNA segments encoding bovine IL-.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.
摘要:
Cloning and expression of nucleotide DNA segments encoding bovine IL-1.beta., and processes for producing purified bovine IL-1.beta. as a product of recombinant cell culture, are disclosed.
摘要:
Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma.
摘要:
The present invention provides an isolated DNA sequence encoding soluble and membrane bound forms of a mammalian IgA Fc receptor, as well as recombinant expression vectors and host cells suitable for expressing the protein.
摘要:
The present invention provides soluble CD39 polypeptides and compositions, and methods for inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide.
摘要:
The biological activity of exogenous ligand proteins is enhanced by intravenously co-administering to a mammal the ligand and a soluble receptor protein that binds thereto. Pharmaceutical compositions comprising a ligand protein complexed with a soluble receptor protein are provided. In certain embodiments, the ligand is selected from the group consisting of interleukins, colony stimulating factors, and tumor necrosis factor.